| Business Summary | | Celeris
Corporation
is
a
provider
of
specialty
clinical
research
and
information
technology
services
that
expedite
and
streamline
clinical
trial
and
regulatory
submission
process
for
pharmaceutical,
medical
device
and
biotechnology
manufacturers.
These
services
accelerate
specific
functions
within
clinical
trials
and
new
product
submissions,
which
often
become
bottlenecks
for
manufacturers
seeking
regulatory
clearance
to
market
new
products.
Delays
in
obtaining
regulatory
clearance
for
new
products
can
result
in
significant
lost
revenues
and
increased
expenses
for
manufacturers.
As
a
consequence,
manufacturers
have
increasingly
outsourced
clinical
research
functions
to
organizations,
such
as
the
Company,
that
can
offer
expertise
and
services
that
speed
the
product
development
process. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Celeris
Corporation
provides
specialty
clinical
research
to
pharmaceutical,
medical
device
and
biotechnology
manufacturers.
For
the
six
months
ended
6/30/01,
revenues
decreased
20%
to
$4.9
million.
Net
loss
decreased
23%
to
$1.4
million.
Results
reflect
decreases
in
the
regulatory
consulting
segment
due
to
decreased
services
performed,
offset
by
improved
margins
due
to
increased
utilization
of
client
service
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Nehra, 52 Chairman | -- | Barbara Cannon, 49 Pres,
CEO, Director | $279K | Paul Johnson, 35 CFO,
VP, Sec. | 165K | Donald Fortin, M.D., 43 VP | 180K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|